Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D. Hellmann(Memorial Sloan Kettering Cancer Center), Naiyer A. Rizvi(Memorial Sloan Kettering Cancer Center), Jonathan W. Goldman(UCLA Jonsson Comprehensive Cancer Center), Scott Gettinger(Yale Cancer Center), Hossein Borghaei(Fox Chase Cancer Center), Julie R. Brahmer(Sidney Kimmel Comprehensive Cancer Center), Neal Ready(Duke Medical Center), David E. Gerber(The University of Texas Southwestern Medical Center), Laura Q.M. Chow(University of Washington), Rosalyn A. Juergens(McMaster University), Frances A. Shepherd(University of Toronto), Scott A. Laurie(University of Ottawa), William J. Geese(Bristol-Myers Squibb (United States)), Shruti Agrawal(Bristol-Myers Squibb (United States)), Tina C. Young(Bristol-Myers Squibb (United States)), Xuemei Li(Bristol-Myers Squibb (United States)), Scott Antonia(Moffitt Cancer Center)
The Lancet Oncology
December 5, 2016
10.1016/s1470-2045(16)30624-6
Cited by 958Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis